Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.92USD
18 May 2018
Change (% chg)

$-0.01 (-0.17%)
Prev Close
$5.93
Open
$5.95
Day's High
$6.00
Day's Low
$5.86
Volume
88,754
Avg. Vol
186,736
52-wk High
$9.69
52-wk Low
$3.83

Select another date:

Thu, May 10 2018

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share

* PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

Select another date: